FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
